The treatment of acute myeloblastic leukemia (AML) has been considerably modified over the years. The Argentine Group for the Treatment of Acute Leukemia (GATLA) was created in 1967 with the purpose ...

Combining proteasome inhibitors with autophagy inhibitors disrupts acute myeloid leukemia (AML) cells' proteostasis, enhancing treatment efficacy and inducing programmed cell death. The novel therapy ...

COPENHAGEN, Denmark ― Even after chemotherapy for acute myeloid leukemia (AML) has pushed the patient into remission, there remain some preleukemic genetic mutations. New research shows that these ...

Acute myeloid leukemia (AML) is a progressive type of cancer that affects your bone marrow and blood cells. Early detection and treatment are important to help increase the chances of survival from ...

Acute myeloid leukemia (AML) is a type of blood and bone marrow cancer. It affects the ability of your bone marrow to produce normal-functioning white blood cells (WBCs). The risk of this type of ...

The overall 5-year relative survival rate for AML is about 30%, but this number is an estimate based on a large group of people and does not predict individual outcomes. Younger people with AML tend ...